Last Friday, the Reagan-Udall Foundation held a public meeting to discuss the advancement of treatments for PTSD, which includes psychedelics.

A new report from the Reagan-Udall Foundation for the FDA explores which parts of the rule are confusing to executives that are working to bring their companies into alignment with the rule.

New labels would inform consumer whether the products are high in added sugars, sodium or saturated fats.

The press conference followed the FDA and Reagan-Udall Foundation's public meeting on PTSD, which included discussions on psychedelic therapy.

Read more

The Sept. 6 hybrid public meeting, hosted by the Reagan-Udall Foundation for the FDA, drew experts, advocates and critics to discuss how to move forward advancing PTSD treatment. While the official agenda skirted the recent MDMA decision, public comments and a subsequent press briefing brought a spotlight back on the issue.

In the spring, the Reagan-Udall Foundation for the FDA held a series of roundtable discussions with invited stakeholders. These conversations focused on the Food Safety Modernization Act’s Requirements for Additional Traceability Records for Certain Foods, commonly known as the food traceability rule.

Read more

The Reagan-Udall Foundation for the Food and Drug Administration is a nonprofit organization that was created by Congress to advance the mission of the FDA. The Foundation held a meeting recently entitled “Advancing Treatments for Post-Traumatic Stress Disorder” to discuss efforts to accelerate the development of treatments for PTSD, including psychedelic therapies.

The discussion, hosted by the Reagan-Udall Foundation for the Food and Drug Administration, a nonprofit formed by Congress to support FDA, didn’t focus specifically on psychedelic-assisted therapies, but the topic nevertheless featured prominently—especially during a stakeholder comment session where most spoke in favor of wider access to MDMA and other emerging treatments.